{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-139962","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2024-12-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.425406+00:00","generated_at":"2026-05-28T23:16:37.956675+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Assembly Biosciences reports interim Phase 1b data for ABI-4334 with 2.9 log10 IU/mL mean HBV DNA reduction","bullets":["ABI-4334 was well-tolerated with favorable safety profile; no serious adverse events or discontinuations in either cohort.","In 150 mg dose cohort, mean HBV DNA declined 2.9 log10 IU/mL and mean HBV RNA declined 2.5 log10 U/mL over 28 days.","Half-life supports once-daily oral dosing; Cmin multiples above EC50 for antiviral activity and cccDNA inhibition.","Enrollment ongoing for 400 mg cohort, expected final cohort; data anticipated in first half of 2025.","Gilead Sciences has opt-in rights to further develop and commercialize ABI-4334 after completion of Phase 1b study."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-139962","json":"https://secwatch.observer/filing/0000950170-24-139962.json","markdown":"https://secwatch.observer/filing/0000950170-24-139962.md","text":"https://secwatch.observer/filing/0000950170-24-139962.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024139962/0000950170-24-139962-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024139962/asmb-20241226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-28T23:16:37.956675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}